Reuters logo
Pfizer sues Johnson & Johnson over Remicade biosimilar
September 20, 2017 / 1:44 PM / in a month

Pfizer sues Johnson & Johnson over Remicade biosimilar

Sept 20 (Reuters) - Pfizer Inc on Wednesday filed a lawsuit against Johnson & Johnson, saying that the drugmaker’s anticompetitive contracts with health insurers prevented biosimilar competition to its blockbuster rheumatoid arthritis drug, Remicade.

Remicade generated U.S. sales of $4.8 billion in 2016.

The case was filed in the U.S. District Court for the Eastern District of Pennsylvania. (Reporting by Divya Grover in Bengaluru; Editing by Sriraj Kalluvila)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below